Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

Partial nephrectomy versus radical nephrectomy for low risk kidney cancer

This study looked at the survival of patients following partial nephrectomy versus radical nephrectomy for low-risk renal cell carcinoma (RCC). A total of 1995 patients were included in the study and 53% had partial nephrectomy. The size of the tumour, the grade of the tumour (how aggressive it was), the number of blood vessels supplying […]

read more

Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs

This phase 2 study looked at the use of stereotactic radiotherapy to treat metastatic renal cell carcinoma (RCC) in patients where the cancer had spread and there were a small number of metastases. These patients were on a tyrosine kinase inhibitor as the first or second medicine for their cancer. The aim of the study […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer

KEYNOTE-427 is an open-label, single-arm, phase II study to look at the effectiveness of pembrolizumab as a first-line treatment for people with advanced clear cell RCC. At ESMO this year, updated efficacy, and safety results after a minimum follow-up of 41 months were presented. This study looked at the treatment of people with RCC with […]

read more

ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

The use of two medicines together (combination therapies) for previously untreated patients with RCC that has spread (metastatic RCC) is fast becoming standard treatment for these patients. A study called CheckMate-214 showed that a combination of the immune checkpoint inhibitors nivolumab plus ipilimumab helped patients with intermediate or high risk RCC live longer than those […]

read more

ESMO 2021: Pembrolizumab as adjuvant therapy

Adjuvant therapy is medication that is given in addition to surgery to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma; however, the cancer can […]

read more

ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in several changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. This […]

read more

ESMO 2021: Cabozantinib for collecting duct carcinoma – the BONSAI study

Metastatic collecting duct carcinoma is an aggressive form of RCC, which is poorly researched and understood. There is an unmet need for an effective treatment for these patients, and very few clinical trials allow these patients to take part. This single centre, phase 2 trial tested cabozantinib in untreated patients with collecting duct carcinoma that […]

read more

ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

Ipilimumab plus nivolumab is a standard first-line treatment for patients with intermediate and poor-risk advanced RCC. Serious or life-threatening side effects are relatively common with this combination. The aim of this phase 2 trial (PRISM) was to see if changing the treatment schedule for ipilimumab in combination with nivolumab can improve tolerability of this treatment […]

read more
Showing 21 to 30 of 829 results
  TOP